Place of Modern III Generation Fluoroquinolones in the Treatment of Advanced Peritonitis

N.N. Khachatryan, N.K. Vabischevich, L.V. Okhinko, B.G. Muslumov

Abstract


.

References


Белобородов В.Б. Применение фторхинолонов: проблемы резистентности // Consilium medicum. Приложение «Хирургия». — 2005. — № 2. — С. 13-16.

Брискин Б.С., Дибиров М.Д., Хачатрян Н.Н. Антибактериальная терапия тяжелых форм распространенного перитонита // Consilium Medicum. — 2006.

Гельфанд Б.Р., Карабак В.И., Гельфанд Е.Б., Белоцерковский Б.З., Попов Т.В. Фторхинолоны при лечении инфекций в хирургии и интенсивной терапии: место и эффективность левофлоксацина // Consilium Medicum. Хирургия. — 2006. — № 2. — С. 3-8.

Голуб А.В., Дехнич А.В., Козлов Р.С. Антибактериальная терапия осложненных интраабдоминальных инфекций: от чего зависит успех? // Клиническая микробиология и антимикробная химиотерапия. — 2011. — Т. 13, № 2. — С. 1-5.

Гостищев В.К., Сажин В.П., Авдовенко А.Л. Перитонит. — М., 2006.

Ерюхин И.А., Багненко С.Ф., Григорьев Е.Г. и др. Абдоминальная хирургическая инфекция: современное состояние и ближайшее будущее в решении актуальной клинической проблемы // Инфекции в хирургии. — 2007. — № 1. — С. 6-11.

Зайцев А.А. Левофлоксацин в лечении хирургических и генерализованных инфекций // Инфекции в хирургии. — 2004. — № 1. — С. 17-19.

Козлов Р., Козлов С., Голуб А. Фторхинолоны с антианаэробной активностью при полимикробных инфекциях // Врач. — 2009. — С. 25-28.

Савельев В.С., Гельфанд Б.Р., Филимонов М.Н. Перитонит: Практическое руководство. — 2006.

Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина // Инфекции и антимикробная терапия. — 2002. — Т. 4, № 4. — С. 100-107.

Baquero F., Hsueh P.R., Paterson D.L. et al. In vitro susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2005 results from Study for Moni-toring Antimicrobial Resistance Trends (SMART) // Surg. Infect. (Larchmit). — 2008 [Epnb ahead of print].

Bare M. et al. Presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, 2002.

Brink Adrian J., Botha Roelof F., Poswa Xolisma et al. Antimicrobial Sus-ceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in South African Hospitals (SMART Study 2004–2009) // Surgical Infections. — Vol. 13, № 1. — 2012. — Р. 43-49.

Canton R., Loza E., Aznar J. et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002–2010) // Rev. Esp. Quimioter. — 2011. — № 24(4). — Р. 223-232.

Carmelli Y. The role of carbapanems. The predictive factors for multi-drug re-sistant gram-negatives. — 2006.

Chi-Chang Huamg, Yao-Shen Chen, Han-Siong Toh et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002–2010 // International Journal of Antimicrobial Agents. — 2012. — S4-10.

Cornaglia G., Hryniewich W., Jarlier V. et al. European recommendations for antimicrobial resistance surveillance // Clin. Microbiol. Infect. — 2004. — № 10. — Р. 349-383.

Davey P. et al. Presented at the International Society of Pharmacоeconomics and Outcomes Research Sixth Annual International Meeting, Virginia, USA, 2001.

Goldstein E.J., Citon D.M., Peraino V. Effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods after the introduction of ertapenem onto a hospital formulary // Abstracts of the Forthy-foupth Infections Disease Society of America Toronto, Canada. Abstract 280. — 2006. — Р. 98.

Hawser S.P., Bouchillon S.K., Lascols C. et al. Susceptibility of European Escherichia coli clinical isolates from intraabdominal infections, etended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009) // Clin. Microbiol. Infect. — 2011. — № 18. — Р. 253-259.

Eckman Christian et al. Prospective, Non-Interventional, Multi-Centre Trial of Tigecycline in the Treatment of Severely Ill Patients with Complicated infectons // Chemotherapy. — 2011. — № 57. — Р. 275-284.

Hermsen E.D., Hovde L.B., Sprandel K.A. et al. Levofloxacin plus metronidazole administered once daily versus Moxifloxacin Monotherapy against mixed infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model // Antimicrobial Agents and Chemotherapy. — 2005. — Vol. 49, № 2. — Р. 685-689.

Joo E.J., Kang C.I., Ha Y.E. et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection // Infection. — 2011. — № 4(39). — Р. 309-318.

Kozlov R.S., Krechikova O.I., Ivanchik N.V. et al. Etiology of nosocomial Bacterial Infections in Russia. Rosnet Study Group // Proceedings of the 48 Interscience Conference on Antimicrobial Agents and Chemotherapy. 2008. Oct. 25–28; Washington, USA. Р. 572, abstract K-4108.

Krobot K., Yin D., Zhang Q. et al. Effect of inappropiate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery // Eur. J. Clin. Microbiol. Infect. Dis. — 2004. — № 23. — Р. 682-687.

Montravers P., Lepape A., Dubreul L. et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study // Journal of Antimicrobial Chemotherapy. — 2009. — № 63. — Р. 785-794.

Neuhauser M.M., Weinstein R.A., Rydman R. et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolones // JAMA. — 2003. — № 289. — Р. 885-888.

Paterson D.L. «Collateral Damage» from Cephalosporins or Quinolone Antibiotic Therapy // Clinical Infect. Dis. — 2004. — № 38(Suppl. 4). — Р. 341-345.

Paterson D., Rossi F., Baquero F. et al. In vitro susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART) // Journal of Antimicrobial Chemotherapy. — 2005. — № 55. — Р. 965-972.

Rodrigues-Bano J., Alcala J.C., Cisneros J.M. et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli // Arch. Intern. Med. — 2008. — № 168. — Р. 1897-1902.

Umgelter A., Reindl W., Miedaner M., Schmid R.M., Huber W. Failure of Current Antibiotic First-Line Regimes and Mortality in Hospitalized Patients with Spontaneous Bacterial Peritonitis // Infection. — 2009. — № 1. — P. 2-9.




DOI: https://doi.org/10.22141/2224-0586.5.60.2014.83502

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта